成都圣諾生(sheng)(sheng)物科(ke)技(ji)(ji)股份有限(xian)公(gong)(gong)司(以下(xia)簡稱“圣諾生(sheng)(sheng)物”或“公(gong)(gong)司”)是一(yi)家擁有多(duo)(duo)(duo)肽(tai)(tai)合(he)成和修飾核心技(ji)(ji)術(shu)的(de)高新技(ji)(ji)術(shu)企(qi)業,具有先進(jin)、高效的(de)多(duo)(duo)(duo)肽(tai)(tai)藥(yao)物工(gong)藝(yi)研發(fa)和規模化(hua)生(sheng)(sheng)產(chan)能力。公(gong)(gong)司主營業務(wu)(wu)為自主研發(fa)、生(sheng)(sheng)產(chan)和銷售在國內外(wai)具有較(jiao)大(da)市(shi)場容量及(ji)較(jiao)強(qiang)競爭(zheng)力的(de)多(duo)(duo)(duo)肽(tai)(tai)原料藥(yao)和制劑(ji)產(chan)品,同(tong)時公(gong)(gong)司依托在多(duo)(duo)(duo)肽(tai)(tai)藥(yao)物研發(fa)和規模化(hua)生(sheng)(sheng)產(chan)領域的(de)技(ji)(ji)術(shu)優勢,為國內外(wai)醫藥(yao)企(qi)業提(ti)(ti)供多(duo)(duo)(duo)肽(tai)(tai)創新藥(yao)藥(yao)學研究服(fu)(fu)務(wu)(wu)、多(duo)(duo)(duo)肽(tai)(tai)類產(chan)品定制生(sheng)(sheng)產(chan)服(fu)(fu)務(wu)(wu)以及(ji)多(duo)(duo)(duo)肽(tai)(tai)藥(yao)物生(sheng)(sheng)產(chan)技(ji)(ji)術(shu)轉(zhuan)讓服(fu)(fu)務(wu)(wu)。此(ci)外(wai),公(gong)(gong)司還(huan)提(ti)(ti)供小(xiao)分子化(hua)學藥(yao)物左西(xi)孟旦制劑(ji)代加工(gong)及(ji)左西(xi)孟旦原料藥(yao)生(sheng)(sheng)產(chan)、出口銷售業務(wu)(wu)。
圣諾生(sheng)(sheng)(sheng)(sheng)物(wu)具(ju)備多(duo)(duo)肽(tai)(tai)原料藥(yao)(yao)(yao)(yao)和(he)(he)制(zhi)劑的(de)全(quan)流程研發(fa)(fa)管(guan)線和(he)(he)全(quan)產(chan)(chan)業鏈(lian)平臺,能夠為多(duo)(duo)肽(tai)(tai)創(chuang)新(xin)藥(yao)(yao)(yao)(yao)和(he)(he)仿制(zhi)藥(yao)(yao)(yao)(yao)提供從(cong)工(gong)藝路線設計,到小試(shi)(shi)、中(zhong)試(shi)(shi)、工(gong)藝驗(yan)(yan)證(zheng)和(he)(he)質量研究等藥(yao)(yao)(yao)(yao)學(xue)(xue)研究服(fu)務,以及(ji)藥(yao)(yao)(yao)(yao)物(wu)研發(fa)(fa)及(ji)商業化(hua)生(sheng)(sheng)(sheng)(sheng)產(chan)(chan)所需原料藥(yao)(yao)(yao)(yao)、制(zhi)劑產(chan)(chan)品的(de)全(quan)鏈(lian)條定制(zhi)生(sheng)(sheng)(sheng)(sheng)產(chan)(chan)服(fu)務,涵蓋從(cong)藥(yao)(yao)(yao)(yao)物(wu)發(fa)(fa)現、臨(lin)床(chuang)前研究,到臨(lin)床(chuang)試(shi)(shi)驗(yan)(yan)和(he)(he)上市(shi)銷售(shou)的(de)完(wan)整藥(yao)(yao)(yao)(yao)物(wu)開發(fa)(fa)周(zhou)期。公司憑借多(duo)(duo)肽(tai)(tai)合成和(he)(he)修(xiu)飾(shi)核心技術優勢,在多(duo)(duo)肽(tai)(tai)藥(yao)(yao)(yao)(yao)物(wu)研發(fa)(fa)生(sheng)(sheng)(sheng)(sheng)產(chan)(chan)領域獲(huo)得(de)較高的(de)知名度和(he)(he)認可(ke)度,先后(hou)為蘇(su)州派格生(sheng)(sheng)(sheng)(sheng)物(wu)、百(bai)奧泰生(sheng)(sheng)(sheng)(sheng)物(wu)、八(ba)加一(yi)等新(xin)藥(yao)(yao)(yao)(yao)研發(fa)(fa)企業和(he)(he)科研機構提供了30余個項目的(de)藥(yao)(yao)(yao)(yao)學(xue)(xue)研究及(ji)定制(zhi)生(sheng)(sheng)(sheng)(sheng)產(chan)(chan)服(fu)務,其中(zhong)1個多(duo)(duo)肽(tai)(tai)創(chuang)新(xin)藥(yao)(yao)(yao)(yao)已獲(huo)批上市(shi)進入(ru)商業化(hua)階段(duan)(duan),1個多(duo)(duo)肽(tai)(tai)創(chuang)新(xin)藥(yao)(yao)(yao)(yao)已申報生(sheng)(sheng)(sheng)(sheng)產(chan)(chan),另有10個多(duo)(duo)肽(tai)(tai)創(chuang)新(xin)藥(yao)(yao)(yao)(yao)進入(ru)臨(lin)床(chuang)試(shi)(shi)驗(yan)(yan)階段(duan)(duan)。
公司挑選在(zai)國(guo)內(nei)外具有較(jiao)大市(shi)(shi)(shi)場容量及較(jiao)強市(shi)(shi)(shi)場競爭力的(de)(de)(de)多(duo)肽(tai)(tai)仿(fang)制(zhi)藥(yao)品(pin)種(zhong)(zhong)(zhong)進行(xing)研發(fa),已(yi)掌(zhang)握15個(ge)(ge)品(pin)種(zhong)(zhong)(zhong)原(yuan)料藥(yao)的(de)(de)(de)規模(mo)化生(sheng)產(chan)技(ji)術,其中9個(ge)(ge)品(pin)種(zhong)(zhong)(zhong)在(zai)國(guo)內(nei)取得生(sheng)產(chan)批件(jian)、9個(ge)(ge)品(pin)種(zhong)(zhong)(zhong)獲得美國(guo)DMF備案(其中8個(ge)(ge)品(pin)種(zhong)(zhong)(zhong)處于激活狀態),延(yan)伸開發(fa)的(de)(de)(de)8個(ge)(ge)多(duo)肽(tai)(tai)制(zhi)劑(ji)品(pin)種(zhong)(zhong)(zhong)在(zai)國(guo)內(nei)取得了(le)12個(ge)(ge)生(sheng)產(chan)批件(jian),產(chan)品(pin)涵蓋(gai)免疫、消(xiao)化道、抗病(bing)毒、婦產(chan)科、糖尿(niao)病(bing)、心腦血管(guan)、罕見病(bing)、骨科等(deng)等(deng)多(duo)肽(tai)(tai)藥(yao)物發(fa)揮(hui)重要作用的(de)(de)(de)領域(yu)。公司多(duo)肽(tai)(tai)制(zhi)劑(ji)產(chan)品(pin)注(zhu)射用恩夫韋肽(tai)(tai)和卡貝縮(suo)宮素注(zhu)射液(ye)為國(guo)內(nei)首仿(fang)多(duo)肽(tai)(tai)藥(yao)物;比伐蘆定、利拉魯(lu)肽(tai)(tai)、胸(xiong)腺(xian)法新、艾替班特(te)、恩夫韋肽(tai)(tai)等(deng)合成難度較(jiao)大的(de)(de)(de)仿(fang)制(zhi)原(yuan)料藥(yao)已(yi)出(chu)口至歐(ou)美、印(yin)度、韓國(guo)等(deng)國(guo)際市(shi)(shi)(shi)場。